Biogen (BIIB) Statistics

Biogen Inc (BIIB) is a global biotechnology company that specializes in the development and commercialization of therapies for neurological, autoimmune, and hematologic disorders. The company has a strong focus on research and development, with a robust pipeline of potential new treatments. Biogen is listed on the NASDAQ stock exchange and has a current market capitalization of over $50 billion. The stock has a price-to-earnings ratio of 9.5, indicating that it is relatively undervalued compared to its peers in the biotechnology sector. Biogen's valuation metrics also highlight its attractiveness as an investment opportunity. The company has a price-to-sales ratio of 3.7, which is lower than the sector average, suggesting that the stock may be undervalued. Additionally, Biogen has a price-to-book ratio of 3.9, indicating that the stock is trading at a reasonable price relative to its book value.

When it comes to the fundamentals, Biogen Inc stands out as a strong performer. The company has a solid financial position, with a profit margin of 33.2% and a gross profit of $10.5 billion. Biogen also has a manageable level of debt, with a total debt of $6.2 billion. This indicates that the company is in a stable financial position and is able to meet its financial obligations. Biogen's stock performance has also been positive compared to the sector. Over the past year, the stock has generated a return of 16.5%, outperforming the biotechnology sector average. In terms of revenue per share, Biogen has consistently shown growth. The company's revenue per share is $33.67, indicating that it is generating solid sales. Lastly, the CEO of Biogen Inc is Michel Vounatsos, who has been leading the company since 2017. Under his leadership, Biogen has continued to focus on innovation and drive growth in the biotechnology sector.